Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma
Daniel Schäfer,
Stefan Tomiuk,
Laura N. Küster,
Wa’el Al Rawashdeh,
Janina Henze,
German Tischler-Höhle,
David J. Agorku,
Janina Brauner,
Cathrin Linnartz,
Dominik Lock,
Andrew Kaiser,
Christoph Herbel,
Dominik Eckardt,
Melina Lamorte,
Dorothee Lenhard,
Julia Schüler,
Philipp Ströbel,
Jeannine Missbach-Guentner,
Diana Pinkert-Leetsch,
Frauke Alves,
Andreas Bosio and
Olaf Hardt ()
Additional contact information
Daniel Schäfer: Miltenyi Biotec GmbH, R&D
Stefan Tomiuk: Miltenyi Biotec GmbH, R&D
Laura N. Küster: Miltenyi Biotec GmbH, R&D
Wa’el Al Rawashdeh: Miltenyi Biotec GmbH, R&D
Janina Henze: Miltenyi Biotec GmbH, R&D
German Tischler-Höhle: Miltenyi Biotec GmbH, R&D
David J. Agorku: Miltenyi Biotec GmbH, R&D
Janina Brauner: Miltenyi Biotec GmbH, R&D
Cathrin Linnartz: Miltenyi Biotec GmbH, R&D
Dominik Lock: Miltenyi Biotec GmbH, R&D
Andrew Kaiser: Miltenyi Biotec GmbH, R&D
Christoph Herbel: Miltenyi Biotec GmbH, R&D
Dominik Eckardt: Miltenyi Biotec GmbH, R&D
Melina Lamorte: Charles River Discovery Research Services GmbH
Dorothee Lenhard: Charles River Discovery Research Services GmbH
Julia Schüler: Charles River Discovery Research Services GmbH
Philipp Ströbel: University Medical Center Göttingen, Institute for Pathology
Jeannine Missbach-Guentner: University Medical Center Göttingen, Institute for Diagnostic and Interventional Radiology
Diana Pinkert-Leetsch: University Medical Center Göttingen, Institute for Diagnostic and Interventional Radiology
Frauke Alves: University Medical Center Göttingen, Clinic for Hematology and Medical Oncology
Andreas Bosio: Miltenyi Biotec GmbH, R&D
Olaf Hardt: Miltenyi Biotec GmbH, R&D
Nature Communications, 2021, vol. 12, issue 1, 1-18
Abstract:
Abstract A major roadblock prohibiting effective cellular immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is the lack of suitable tumor-specific antigens. To address this challenge, here we combine flow cytometry screenings, bioinformatic expression analyses and a cyclic immunofluorescence platform. We identify CLA, CD66c, CD318 and TSPAN8 as target candidates among 371 antigens and generate 32 CARs specific for these molecules. CAR T cell activity is evaluated in vitro based on target cell lysis, T cell activation and cytokine release. Promising constructs are evaluated in vivo. CAR T cells specific for CD66c, CD318 and TSPAN8 demonstrate efficacies ranging from stabilized disease to complete tumor eradication with CD318 followed by TSPAN8 being the most promising candidates for clinical translation based on functionality and predicted safety profiles. This study reveals potential target candidates for CAR T cell based immunotherapy of PDAC together with a functional set of CAR constructs specific for these molecules.
Date: 2021
References: Add references at CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/s41467-021-21774-4 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21774-4
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-021-21774-4
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().